Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6946103 | 0.82 | TAAR1 (0.53) | ALDH1A1HTTVNN1GAACTBP2 | |
| SCHEMBL5954642 | 0.81 | L3MBTL1 (0.50) | L3MBTL1TSHRRAB9AALDH1A1NPC1 | |
| SCHEMBL7256785 | 0.79 | ALDH1A1 (0.49) | L3MBTL1RAB9AALDH1A1NPC1VNN1 | |
| SCHEMBL1479915 | 0.78 | NPC1 (0.55) | L3MBTL1RAB9AALDH1A1NPC1HTT | |
| SCHEMBL11221142 | 0.77 | L3MBTL1 (0.58) | L3MBTL1RAB9ANPC1VNN1CTBP2 | |
| SCHEMBL1538218 | 0.76 | ALDH1A1 (0.58) | L3MBTL1RAB9AALDH1A1NPC1VNN1 | |
| SCHEMBL11388782 | 0.76 | CTBP2 (0.50) | L3MBTL1RAB9AALDH1A1NPC1VNN1 | |
| SCHEMBL12731514 | 0.76 | NPC1 (0.46) | L3MBTL1RAB9AALDH1A1NPC1HTT | |
| SCHEMBL11622858 | 0.75 | PPARG (0.47) | L3MBTL1RAB9AALDH1A1NPC1VNN1 | |
| SCHEMBL3070923 | 0.75 | L3MBTL1 (0.52) | L3MBTL1RAB9AALDH1A1NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058374-A1 | Urotensin II receptor agents | ACADIA PHARMACEUTICALS INC. | 2006-03-16 | — | — | US | disclosed |
| US-20040077529-A1 | Urotensin II receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2003104216-A1 | UROTENSIN II RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS INC. (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077529-A1 | Urotensin II receptor agents | UTS2R, PLAUR, GPR17 | L3MBTL1 4695/4885TSHR 367/4885UTS2R 1/4885 |
| US-20060058374-A1 | Urotensin II receptor agents | UTS2R, PLAUR, SCTR | L3MBTL1 4725/4885TSHR 316/4885UTS2R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.